Blood Pressure Drugs Linked to Better Colitis Outcomes
A study of vedolizumab-treated ulcerative colitis patients links ACE inhibitors and ARBs to fewer hospitalizations and colon-removal surgeries.
Updated on Nov. 13, 2026 in Heart Disease

Researchers from Northwestern Medicine and Kiel University found that ulcerative colitis patients taking ACE inhibitors or ARBs alongside vedolizumab were less likely to be hospitalized or undergo colon-removal surgery. The findings, drawn from more than 1,300 patients in two clinical trials, were published in Nature Medicine.
Why it matters
The association points to a possible way to predict which patients will respond poorly to vedolizumab, a common treatment for the condition. Clinical trials are still needed to confirm the findings before any change in care is considered.
The analysis covered more than 1,300 patients in two vedolizumab trials and nearly 9,000 ulcerative colitis patients with hypertension, and only ACE inhibitors and ARBs showed the association, not other antihypertensive classes. Whether the link holds for patients with normal blood pressure, and whether it is causal, remains unresolved pending clinical trials.
The players
Northwestern Medicine
Northwestern Medicine is the academic medical center affiliated with Northwestern University in Chicago, known for its clinical research and medical education programs.
Kiel University
Kiel University is a public research university in Kiel, Germany, known for its work in medicine and the life sciences.
The details
Researchers tracked symptom changes such as stool frequency and rectal bleeding to identify response patterns, and analyzed tissue biopsies and blood samples. The tissue and blood work linked poor vedolizumab response to vascular inflammation in the colon, and the team is developing a diagnostic test based on markers identified in non-responders.
Timeline
13 November 2026: Findings were published in Nature Medicine.
Health Landscape
The findings extend the vedolizumab trial program by suggesting that commonly prescribed blood-pressure drugs may influence how ulcerative colitis patients respond to biologic therapy. The shift points toward treatment decisions informed by a patient's existing medications rather than the biologic alone.
For patients with ulcerative colitis who already take ACE inhibitors or ARBs, this research does not by itself change treatment, and patients should not start or stop any medication without consulting their doctor. Future clinical trials will determine whether these findings should influence how vedolizumab is prescribed.
The takeaway
Patients with ulcerative colitis should discuss all their current medications with their doctor, since existing treatments may affect how well a biologic works. Any change in care should wait for confirmation from clinical trials.
Further reading
For related coverage of blood-pressure medicines and their broader effects, see Heart Disease.
Source note: This article includes information reported by Quicknews.



